BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
The use of cannabis would not be a reason to deny compensation for workplace injuries in some circumstances, under a bill moving through the Kansas Legislature this week.
S.B. 158, of which hearings are taking place, would also explicitly exempt workers compensation from having to pay for the drug.
Kansas law already declares employers are not liable when the use of alcohol or drugs contributes to a workplace injury. The bill would declare that compensation “shall not be denied” in the case of a worker who is a registered medical cannabis patient, was using the drug in accordance with the proposed law “and there has been no prior incidence of the employee’s impairment on the job as a result of the use of such cannabis or cannabis derivative within the previous 24 months.”
The proposed language mirrors a current statute that prohibits denying claims caused by the use of prescription drugs.
The Senate Committee on Interstate Cooperation heard testimony from bill proponents Tuesday and is taking testimony from opponents at 10:30 a.m. Wednesday.
WorkCompCentral is a sister publication of Business Insurance. More stories here.
Kansas state officials are under fire for redacting large swaths of an audit on prescription drug spending in the state, according to the Hays Post. The Kansas Department of Administration argued that it needed to redact a watchdog report on how the PBM unit of CVS Health Inc. handles prescription drug coverage for Kansas employees, their families and retirees to protect trade secrets. But the redacted details go to the heart of the state health plan, such as how many prescriptions it covered in 2018 and 2019 and their cost, critics say.